Ingevity Corp. announced that it will increase caprolactone monomer capacity at its facility in Warrington, U.K., through a series of optimization projects over the next 12 months that are expected to increase Ingevity’s global monomer production capacity by over 20% and position the company to better meet demand and more effectively serve customers.

 

“We continue to experience growth in demand for the high-performance, sustainable solutions in our engineered polymers Capa portfolio,” said Mike Smith, executive vice president and president, Performance Chemicals. “We are committed to continued investment in innovation, production and customer partnerships to meet the expanding requirements of customers in a variety of end-use markets.” Smith added this exciting news follows recent announcements that the company will open a new innovation center in Warrington at the end of 2021 and add polyol production capabilities at its DeRidder, Louisiana, facility in the second quarter of 2022.

 

“This capacity expansion in Warrington will better position Ingevity to meet increased global demand for our Capa derivative technologies, improve the reliability of monomer supply in the merchant market and enhance service for customers across the globe,” said Steve Hulme, Ingevity’s vice president, engineered polymers.